BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

667 related articles for article (PubMed ID: 27888629)

  • 1. Inhibition of BCR signaling using the Syk inhibitor TAK-659 prevents stroma-mediated signaling in chronic lymphocytic leukemia cells.
    Purroy N; Carabia J; Abrisqueta P; Egia L; Aguiló M; Carpio C; Palacio C; Crespo M; Bosch F
    Oncotarget; 2017 Jan; 8(1):742-756. PubMed ID: 27888629
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Spleen tyrosine kinase inhibition prevents chemokine- and integrin-mediated stromal protective effects in chronic lymphocytic leukemia.
    Buchner M; Baer C; Prinz G; Dierks C; Burger M; Zenz T; Stilgenbauer S; Jumaa H; Veelken H; Zirlik K
    Blood; 2010 Jun; 115(22):4497-506. PubMed ID: 20335218
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective, novel spleen tyrosine kinase (Syk) inhibitors suppress chronic lymphocytic leukemia B-cell activation and migration.
    Hoellenriegel J; Coffey GP; Sinha U; Pandey A; Sivina M; Ferrajoli A; Ravandi F; Wierda WG; O'Brien S; Keating MJ; Burger JA
    Leukemia; 2012 Jul; 26(7):1576-83. PubMed ID: 22362000
    [TBL] [Abstract][Full Text] [Related]  

  • 4. B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406.
    Quiroga MP; Balakrishnan K; Kurtova AV; Sivina M; Keating MJ; Wierda WG; Gandhi V; Burger JA
    Blood; 2009 Jul; 114(5):1029-37. PubMed ID: 19491390
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual SYK/JAK inhibition overcomes ibrutinib resistance in chronic lymphocytic leukemia: Cerdulatinib, but not ibrutinib, induces apoptosis of tumor cells protected by the microenvironment.
    Guo A; Lu P; Coffey G; Conley P; Pandey A; Wang YL
    Oncotarget; 2017 Feb; 8(8):12953-12967. PubMed ID: 28088788
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dasatinib inhibits B cell receptor signalling in chronic lymphocytic leukaemia but novel combination approaches are required to overcome additional pro-survival microenvironmental signals.
    McCaig AM; Cosimo E; Leach MT; Michie AM
    Br J Haematol; 2011 Apr; 153(2):199-211. PubMed ID: 21352196
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Dual Syk/JAK Inhibitor Cerdulatinib Antagonizes B-cell Receptor and Microenvironmental Signaling in Chronic Lymphocytic Leukemia.
    Blunt MD; Koehrer S; Dobson RC; Larrayoz M; Wilmore S; Hayman A; Parnell J; Smith LD; Davies A; Johnson PWM; Conley PB; Pandey A; Strefford JC; Stevenson FK; Packham G; Forconi F; Coffey GP; Burger JA; Steele AJ
    Clin Cancer Res; 2017 May; 23(9):2313-2324. PubMed ID: 27697994
    [No Abstract]   [Full Text] [Related]  

  • 8. BCR signaling in chronic lymphocytic leukemia and related inhibitors currently in clinical studies.
    Robak T; Robak P
    Int Rev Immunol; 2013 Aug; 32(4):358-76. PubMed ID: 23617253
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Microenvironmental stromal cells abrogate NF-κB inhibitor-induced apoptosis in chronic lymphocytic leukemia.
    Simon-Gabriel CP; Foerster K; Saleem S; Bleckmann D; Benkisser-Petersen M; Thornton N; Umezawa K; Decker S; Burger M; Veelken H; Claus R; Dierks C; Duyster J; Zirlik K
    Haematologica; 2018 Jan; 103(1):136-147. PubMed ID: 29122993
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disruption of in vivo Chronic Lymphocytic Leukemia Tumor-Microenvironment Interactions by Ibrutinib--Findings from an Investigator-Initiated Phase II Study.
    Niemann CU; Herman SE; Maric I; Gomez-Rodriguez J; Biancotto A; Chang BY; Martyr S; Stetler-Stevenson M; Yuan CM; Calvo KR; Braylan RC; Valdez J; Lee YS; Wong DH; Jones J; Sun C; Marti GE; Farooqui MZ; Wiestner A
    Clin Cancer Res; 2016 Apr; 22(7):1572-82. PubMed ID: 26660519
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spleen Tyrosine Kinase Is Involved in the CD38 Signal Transduction Pathway in Chronic Lymphocytic Leukemia.
    Benkisser-Petersen M; Buchner M; Dörffel A; Dühren-von-Minden M; Claus R; Kläsener K; Leberecht K; Burger M; Dierks C; Jumaa H; Malavasi F; Reth M; Veelken H; Duyster J; Zirlik K
    PLoS One; 2016; 11(12):e0169159. PubMed ID: 28036404
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting antigen-independent proliferation in chronic lymphocytic leukemia through differential kinase inhibition.
    Slinger E; Thijssen R; Kater AP; Eldering E
    Leukemia; 2017 Dec; 31(12):2601-2607. PubMed ID: 28462919
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adhesion of ZAP-70+ chronic lymphocytic leukemia cells to stromal cells is enhanced by cytokines and blocked by inhibitors of the PI3-kinase pathway.
    Lafarge ST; Johnston JB; Gibson SB; Marshall AJ
    Leuk Res; 2014 Jan; 38(1):109-15. PubMed ID: 23981382
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SYK inhibition thwarts the BAFF - B-cell receptor crosstalk and thereby antagonizes Mcl-1 in chronic lymphocytic leukemia.
    Paiva C; Rowland TA; Sreekantham B; Godbersen C; Best SR; Kaur P; Loriaux MM; Spurgeon SEF; Danilova OV; Danilov AV
    Haematologica; 2017 Nov; 102(11):1890-1900. PubMed ID: 28838991
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TLR Signaling Is Activated in Lymph Node-Resident CLL Cells and Is Only Partially Inhibited by Ibrutinib.
    Dadashian EL; McAuley EM; Liu D; Shaffer AL; Young RM; Iyer JR; Kruhlak MJ; Staudt LM; Wiestner A; Herman SEM
    Cancer Res; 2019 Jan; 79(2):360-371. PubMed ID: 30498085
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The phosphoinositide-3-kinase (PI3K)-delta and gamma inhibitor, IPI-145 (Duvelisib), overcomes signals from the PI3K/AKT/S6 pathway and promotes apoptosis in CLL.
    Balakrishnan K; Peluso M; Fu M; Rosin NY; Burger JA; Wierda WG; Keating MJ; Faia K; O'Brien S; Kutok JL; Gandhi V
    Leukemia; 2015 Sep; 29(9):1811-22. PubMed ID: 25917267
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of constitutive and BCR-induced Syk activation downregulates Mcl-1 and induces apoptosis in chronic lymphocytic leukemia B cells.
    Gobessi S; Laurenti L; Longo PG; Carsetti L; Berno V; Sica S; Leone G; Efremov DG
    Leukemia; 2009 Apr; 23(4):686-97. PubMed ID: 19092849
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of spleen tyrosine kinase in the pathogenesis of chronic lymphocytic leukemia.
    Feng G; Wang X
    Leuk Lymphoma; 2014 Dec; 55(12):2699-705. PubMed ID: 24547708
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of functional sphingosine-1 phosphate receptor-1 is reduced by B cell receptor signaling and increased by inhibition of PI3 kinase δ but not SYK or BTK in chronic lymphocytic leukemia cells.
    Till KJ; Pettitt AR; Slupsky JR
    J Immunol; 2015 Mar; 194(5):2439-46. PubMed ID: 25632006
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decreased NOTCH1 Activation Correlates with Response to Ibrutinib in Chronic Lymphocytic Leukemia.
    Del Papa B; Baldoni S; Dorillo E; De Falco F; Rompietti C; Cecchini D; Cantelmi MG; Sorcini D; Nogarotto M; Adamo FM; Mezzasoma F; Silva Barcelos EC; Albi E; Iacucci Ostini R; Di Tommaso A; Marra A; Montanaro G; Martelli MP; Falzetti F; Di Ianni M; Rosati E; Sportoletti P
    Clin Cancer Res; 2019 Dec; 25(24):7540-7553. PubMed ID: 31578228
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.